Skip to main content

Table 1 Correlation of miR-200s cluster expression with clinical/laboratory features in AML patients

From: Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia

Patient’s features

miR-200a expression

miR-200b expression

miR-429 expression

miR-200c expression

miR-141 expression

Low (n = 49)

High (n = 49)

P

Low (n = 49)

High (n = 49)

P

Low (n = 49)

High (n = 49)

P

Low (n = 49)

High (n = 49)

P

Low (n = 49)

High (n = 49)

P

Sex (male/female)

36/13

23/26

0.013

32/17

27/22

0.409

31/18

28/21

0.680

32/17

27/22

0.409

31/18

28/21

0.680

Age (years)

58 (21–81)

61 (18–87)

0.842

60 (18–81)

59 (18–87)

0.831

60 (21–81)

59 (18–87)

0.741

60 (18–81)

59 (18–87)

0.743

60 (18–81)

59 (18–87)

1.000

WBC (× 109/L)

38.7 (1.3–528.0)

9.6 (1.1–130.2)

0.001

35.5 (1.3–528.0)

9.6 (1.1–130.2)

0.041

34.5 (1.3–528.0)

13.3 (1.1–130.2)

0.099

34.9 (1.3–528.0)

13.2 (1.1–130.2)

0.094

35.5 (1.3–528.0)

10.2 (1.1–116.6)

0.090

Hemoglobin (g/L)

78 (53–138)

76.5 (32–144)

0.085

80 (53–138)

76.5 (32–144)

0.330

77 (32–138)

78 (34–134)

0.940

84 (53–138)

76 (32–144)

0.124

88 (53–138)

74.5 (32–144)

0.024

Platelets (× 109/L)

37 (3–447)

47 (4–264)

0.558

37 (3–447)

46 (4–264)

0.460

36 (3–447)

47 (4–264)

0.512

30 (5–447)

49 (3–264)

0.233

40 (5–125)

46 (3–447)

0.769

BM blasts (%)

60% (20–99%)

58% (20–95%)

0.892

63% (20–99%)

58% (21–95%)

0.651

60% (20–98%)

59% (20–99%)

0.757

63% (20–99%)

54% (20–95%)

0.226

62% (20–98%)

57% (20–99%)

0.598

FAB subtypes

  

0.660

  

0.945

  

0.681

  

0.827

  

0.900

 M0

1

0

 

1

0

 

0

1

 

1

0

 

1

0

 

 M1

4

2

 

3

3

 

3

3

 

2

4

 

2

4

 

 M2

26

24

 

23

27

 

22

28

 

23

27

 

24

26

 

 M4

12

15

 

14

13

 

15

12

 

15

12

 

15

12

 

 M5

6

6

 

7

5

 

8

4

 

7

5

 

6

6

 

 M6

0

2

 

1

1

 

1

1

 

1

1

 

1

1

 

Karyotypes

  

0.982

  

0.813

  

0.606

  

0.948

  

0.578

 Normal

25

28

 

23

30

 

23

30

 

24

29

 

24

29

 

 t(8;21)

5

5

 

5

5

 

6

4

 

5

5

 

6

4

 

 + 8

2

1

 

2

1

 

2

1

 

2

1

 

3

0

 

 − 5/5q-

1

2

 

2

1

 

2

1

 

2

1

 

2

1

 

 − 7/7q-

1

0

 

1

0

 

0

1

 

1

0

 

1

0

 

 t(9;22)

1

0

 

1

0

 

0

1

 

1

0

 

1

0

 

 Complex

8

7

 

9

6

 

10

5

 

8

7

 

7

8

 

 Others

6

5

 

6

5

 

6

5

 

6

5

 

5

6

 

 No data

0

1

 

0

1

 

0

1

 

0

1

 

0

1

 

Gene mutations

 CEBPA (±)

7/33

6/38

0.765

5/38

8/33

0.376

8/36

5/35

0.555

7/34

6/37

0.768

6/37

7/34

0.768

 NPM1 (±)

5/35

4/40

0.730

3/40

6/35

0.307

4/40

5/35

0.730

5/36

4/39

0.735

4/39

5/36

0.735

 FLT3-ITD (±)

6/34

3/41

0.298

6/37

3/38

0.484

6/38

3/37

0.488

5/36

4/39

0.735

6/37

3/38

0.484

 C-KIT (±)

1/39

1/43

1.000

1/42

1/40

1.000

1/43

1/39

1.000

1/40

1/42

1.000

1/42

1/40

1.000

 N/K-RAS (±)

4/36

6/38

0.741

3/40

7/34

0.190

5/39

5/35

1.000

6/35

4/39

0.515

6/37

4/37

0.739

 IDH1/2 (±)

1/39

3/41

0.618

3/40

1/40

0.616

4/40

0/40

0.118

4/37

0/43

0.052

2/41

2/39

1.000

 DNMT3A (±)

4/36

2/42

0.418

4/39

2/39

0.676

4/40

2/38

0.678

3/38

3/40

1.000

3/40

3/38

1.000

 U2AF1 (±)

2/38

2/42

1.000

1/42

3/38

0.354

1/43

3/37

0.343

2/39

2/41

1.000

3/40

1/40

0.616

 SRSF2 (±)

1/39

3/41

0.618

1/42

3/38

0.354

1/43

3/37

0.343

1/40

3/40

0.616

1/42

3/38

0.354

 SETBP1 (±)

2/38

0/44

0.224

2/41

0/41

0.494

2/42

0/40

0.495

2/39

0/43

0.235

2/41

0/41

0.494

 CR (±)

16/33

23/26

0.215

14/35

25/24

0.038

14/35

25/24

0.038

14/35

25/24

0.038

15/34

24/25

0.098

  1. WBC white blood cells, BM bone marrow, FAB French–American–British classification, CR complete remission
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us